Biofarma Group acquires contract manufacturer US Pharma Lab
US Pharma Lab specializes in custom development, manufacture, and distribution of nutraceutical products, including probiotics, vitamins, and minerals.
Photo © iStockphoto.com
Biofarma Group (Milan), a company that develops, manufactures, and packages dietary supplements, medical devices, and probiotic-based drugs and cosmetics for third-party companies, has acquired U.S.-based contract manufacturer US Pharma Lab (North Brunswick, NJ). US Pharma Lab specializes in custom development, manufacture, and distribution of nutraceutical products, including probiotics, vitamins, and minerals.
The companies say this is Biofarma Group’s first acquisition of a contract manufacturer solely focused on nutraceuticals that offers 1) global production in the United States, Europe (Italy and France), and China, 2) “strong innovation capabilities on both sides of the Atlantic, with expertise in probiotics and other nutraceutical products, and 3) “a highly complementary customer base focused on pharma clients, CPGs, and digitally native brands.”
Biofarma Group is controlled by Ardian and the Scarpa family. Amol Luhadia, CEO of US Pharma Lab, who will continue leading US Pharma Lab in the U.S., stated in a press release, “Biofarma Group, Ardian, and the Scarpa family are the perfect partners to transition our family’s business into its next chapter. Biofarma Group’s culture of entrepreneurship and innovation is highly complementary to US Pharma Lab’s; therefore, I am confident that US Pharma Lab’s core values and its ability to provide differentiated solutions to customers will be upheld and strengthened following the acquisition.”
Germano Scarpa, chairman of Biofarma Group, added, “Together, Biofarma Group and US Pharma Lab will be able to offer a variety of best-in-class technologies which are better able to serve all our customers’ needs. The combination will also provide further opportunity to accelerate expansion into new geographic markets and develop new technological capabilities.”
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
